

I hereby certify that this correspondence is deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, Washington, DC 20231" on


Atty Dkt No. 3100-0001.20

PATENT

GP 1615

OCT 8 12 2002
TECH CENTER 1600/2900

RECEIVED



Date

Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re: application of:

Bret BERNER et al.

Serial No.: 10/024,932

Group Art Unit: 1615

Filing Date: December 18, 2001

Examiner: Unassigned

Title: GASTRIC RETENTIVE ORAL DOSAGE FORM WITH RESTRICTED DRUG RELEASE IN THE LOWER GASTROINTESTINAL TRACT

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Washington, DC 20231

Sir:

This is a Supplemental Information Disclosure Statement submitted for the Examiner's consideration. Applicants respectfully request that the Examiner review and make of record the references identified below.

A PTO-1449 form listing the references accompanies this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record. The references are as follows:

FOREIGN PATENT DOCUMENT		
Document No.	Publication Date	Country
GB 1330829	9/19/73	United Kingdom

NONPATENT DOCUMENTS	
Conte et al. (1996), "Modulation of the Dissolution Profiles from Geomatrix® Multi-Layer Matrix Tablettes Containing Drugs of Different Solubility," <i>Biomaterials</i> 17(9):889-896.	
Lapidus et al. (1966), "Some Factors Affecting the Release of a Water-Soluble Drug from a Compressed Hydrophilic Matrix," <i>Journal of Pharmaceutical Sciences</i> 55(8):840-843.	
Maggi et al. (2000), "Highly Swellable, Multi-Layer Tablets to Prolong the Residence Time of the Delivery Device in the Stomach," <i>Abstracts / Journal of Controlled Release</i> 64:333-334.	
Shameem et al. (1995), "Oral Solid Controlled Release Dosage Forms: Role of GI-Mechanical Destructive Forces and Colonic Release in Drug Absorption Under Fasted and Fed Conditions in Humans," <i>Pharmaceutical Research</i> 12(7):1049-1054.	

This Supplemental Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this

application does not exist, or that any of the above references constitutes prior art to the present application within the meaning of 35 USC § 102.

As applicants have not yet received a first Action on the merits, no fee is required for filing this Supplemental Information Disclosure Statement. If, however, the PTO finds that for some reason a fee is found to be necessary, our Deposit Account No. 18-0580 may be charged therefor. **A duplicate copy of this paper is enclosed.**

Respectfully submitted,

By:



Dianne E. Reed
Registration No. 31,292

REED & ASSOCIATES
800 Menlo Avenue, Suite 210
Menlo Park, California 94025
(650) 330-0900 Telephone
(650) 330-0980 Facsimile